AKRO(Delisted)
Akero Therapeutics (AKRO) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Akero Therapeutics market cap is -- and enterprise value is --.
Share Statistics
Akero Therapeutics has 82.32M shares outstanding, with a free float of 72.84M.
Valuation Ratios
Akero Therapeutics's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Solvency
Akero Therapeutics debt-to-equity ratio is 0 and debt-to-assets ratio is 0.05.
Liquidity
Akero Therapeutics's current ratio is 15.83, quick ratio is 15.83, and cash ratio is 15.48, showing its short-term liquidity position.
Return on Capital
Akero Therapeutics's ROE is -34.53%, ROA is -32.12%, and ROIC is -38.13%, showing its return on capital profile.
Profitability
Akero Therapeutics gross margin is --, operating margin is --, and net margin is --.
Operating Efficiency
Akero Therapeutics's asset turnover is 0, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.
Income Statement
Akero Therapeutics's revenue is --, gross profit is --, net income is -292.82M, and EBITDA is -332.84M.
Balance Sheet
Akero Therapeutics's total debt is 0, net debt is -737.83M, total equity is 957.64M, and cash is 737.83M.
Cash Flow Statement
Akero Therapeutics's operating cash flow is -250.17M, free cash flow is -250.17M, and CapEx is --.
Dividends & Yields
Akero Therapeutics dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Akero Therapeutics's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A clinical-stage company that develops transformational treatments for serious metabolic diseases
Per Share Metrics
Akero Therapeutics's EPS is -3.75, book value per share is 11.95, and free cash flow per share is --.
